Search
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalAbnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in … [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376]
Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-Ferric pyrophosphate
go.drugbank.com/drugs/DB09147ApprovedInvestigationalThe ferric ion is strongly complexed by pyrophosphate.[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Ambrosia artemisiifolia pollen
go.drugbank.com/drugs/DB10385ApprovedAmbrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnDNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. … Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
Categories: Topoisomerase II InhibitorsDroxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalDroxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. … Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalPiperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550]. … It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].
Dihydroergocornine
go.drugbank.com/drugs/DB11273Approved[T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049] … [A32964] The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid.
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64040,L64041] It is taken by mouth once daily. … [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawn[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. … Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label].
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid